GSK gives up on MAGE-A3 for lung cancer


GlaxoSmithKline (GSK) has ended Phase III testing of its MAGE-A3 lung-cancer vaccine after failing to find a sub-group of patients who could benefit from the therapy.

GSK's move comes less than two weeks after MAGE-A3 failed in the overall trial, which tested the drug for non-small cell lung cancer.

GSK will continue to research the benefits of MAGE-A3 for melanoma in sub-populations after the drug failed in an overall study of subjects with this type of cancer.

MAGE-A3 was designed to help the immune systems of cancer patients prevent the return of the disease after surgery.

GSK's stock is -0.5%.

Shares in Agenus (AGEN), whose QS-21 Stimulon adjuvant, or booster, is used in MAGE-A3, are -9.4%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs